Scientists have tried to craft drugs that speed the elimination of the protein, α-synuclein, or prevent it from clumping. Neurologist and genomicist Clemens Scherzer of Harvard Medical School in Boston and colleagues decided to try a different strategy. “We wanted to find a drug that could turn down the production of α-synuclein,” he says.
ANA member, Rajesh Pahwa, has published new research on the treatment of Parkinson’s Disease. You can reach more about this research here.
The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), found that people with Parkinson’s who injected themselves each week with exenatide for one year performed better in movement (motor) tests than those who injected a placebo.